The coronavirus vaccine race now features three front runners with clinical data, and at least one boasts impressive T-cell responses.
A small trial of inhaled interferon marks a 30-fold increase in Synairgen stock since January, but the endpoints warrant scrutiny.
But the trade-off between efficacy and tolerability could limit mRNA-1273’s use to those who need it least.
An Avastin combination draws a blank in the Imagyn-050 study. Will a combo with a Parp inhibitor fare any better?
A crucial second pivotal trial in uterine fibroids fails to dispel concerns about the company’s linzagolix.
Daridorexant can't reach the heights of its first pivotal study win, but a pooled analysis could still save it.
After Merck’s success with a P2X3 inhibitor hopes were high for Bellus’s similar compound. They are now dashed.
Biontech and Pfizer come roaring back with the first human data on BNT162, a day after Inovio’s effort disappointed.
Biopsy data set up efruxifermin as a strong contender in the race to find an effective Nash treatment.